ArticleJournal of parasitic diseases : official organ of the Indian Society for Parasitology2025
Molecular and serological assessment of the therapeutic efficacy of Ivermectin Loaded nanoparticles on
Article in Journal of parasitic diseases : official organ of the Indian Society for Parasitology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of Moringa oleifera and ivermectin nanoparticles on the immunopathological response during experimental trichinosis in mice.Gut pathogens · 2025Article
- Protective and therapeutic effects of Lactobacillus brevis PQ214320 and Bacillus subtilis PQ198038 Against experimental Trichinella Infection.PLoS neglected tropical diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trichinosis is a real threat to public health that infects humans and animals. Current treatments have high resistance and limited bioavailability. Consequently, it is imperative to enhance the bioavailability of these drugs by developing new agents. So, the purpose of this study was to assess the efficacy of ivermectin-loaded chitosan nanoparticles (CS NPs) and their combination with albendazole (ABZ) on the muscular and intestinal phases of trichinosis. We had eight main groups of mice: non-infected control; infected control; infected and treated with ABZ; infected and treated with ivermectin (IVM); infected and treated with CS NPs; infected and treated with ABZ and IVM; infected and treated with IVM-loaded CS NPS; and infected and treated with ABZ combined with IVM-loaded CS NPS. Two subgroups were formed for each group: a and b for both phases, intestinal and muscular, respectively. Drug efficacy was parasitologically, histopathologically, serologically, and molecularly evaluated. The ABZ combined with IVM-loaded CS NPS-treated group showed the highest statistically significant reduction in adult and encysted larval counts and a noticeable reduction of both intestinal and muscular inflammation. In the treated groups, there was a significant decrease in TNF-α, iNOS, and IFN-γ gene expression when compared with the infected control. Although the level of IL10 was increased in all treated groups. In conclusion, IVM-loaded CS NPS enhanced the efficacy of ABZ against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.